

HCERES

High Council for the Evaluation of Research
and Higher Education

Department of Research Evaluation

report on research unit:

Hémostase et Remodelage Vasculaire post-
ischémique

HERVI

Under the supervision of the following
institutions and research bodies:

Université de Reims Champagne-Ardenne

HCERES

High Council for the Evaluation of Research
and Higher Education

Department of Research Evaluation

In the name of HCERES,¹

Michel Cosnard, president

In the name of the experts committee,²

Carmen Martinez, chairwoman of the
committee

Under the decree No.2014-1365 dated 14 november 2014,

¹ The president of HCERES "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5)

² The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2)

Evaluation report

This report is the sole result of evaluation by the expert committee, the composition of which is specified below.

The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

Unit name: Hémostase et Remodelage Vasculaire post-ischémique

Unit acronym: HERVI

Label requested: EA

Current number: 3801

Name of Director (2016-2017): Mr Philippe NGUYEN

Name of Project Leader (2018-2022): Mr Philippe NGUYEN

Expert committee members

Chair: Ms Carmen MARTINEZ, Université d'Angers

Experts: Mr Hans DECKMYN, University of Leuven, Belgium

Ms Isabelle JOUET-REMY, Université de Rouen

Mr Jean-François SCHVED, Hôpital Saint-Éloi (representative of the CNU)

Scientific delegate representing the HCERES:

Ms Florence PINET

Representatives of supervising institutions and bodies:

Mr Jean-Paul ESCHARD, Faculté de médecine

Mr Laurent LUCAS, Université de Reims Champagne-Ardenne

Mr François-Xavier MAQUART, SFR

Heads of Doctoral Schools:

Mr Jean-Claude MONBOISSE, Doctoral school n°547, "Sciences Technologies Santé "

1 • Introduction

History and geographical location of the unit

EA 3801 "Hémostase et Remodelage Vasculaire post-Ischémique" (HERVI) was created in 2004, restructured in 2008 and certified by the University of Reims Champagne-Ardenne (URCA) in 2012. EA 3801 is one of the groups of the PRES - Reims Amiens. HERVI is located in the Medical Faculty of Reims and in the laboratory of hematology of the CHU of Reims.

Management team

The unit is under the direction of Mr Philippe NGUYEN and the co-direction of Mr Laurent PIEROT.

HCERES nomenclature

Principal domain: SVE2 Cell biology, Imaging, Molecular biology, Biochemistry, Genomics, Systems biology, Development, Structural biology.

Scientific domains

The scientific unit aims at exploring the links between haemostasis and ischemia-reperfusion in order to propose new therapeutic methods of vascular remodelling. The research thematic of the unit is focused on the biology of tissue factor, by studying the role of leukocytes in tissue factor expression in haemostasis to understand the relationship between haemostasis and inflammation.

Key words: Haemostasis, Ischemia, Vascular reparation, Pharmacology.

Unit workforce

Unit workforce	Number on 30/06/2016	Number on 01/01/2018
N1: Permanent professors and similar positions	12	13
N2: Permanent researchers from Institutions and similar positions		
N3: Other permanent staff (technicians and administrative personnel)	3	3
N4: Other researchers (Postdoctoral students, visitors, etc.)	7	
N5: Emeritus		
N6: Other contractual staff (technicians and administrative personnel)		
N7: PhD students	3	
TOTAL N1 to N7	25	
Qualified research supervisors (HDR) or similar positions	8	

Unit record	From 01/01/2011 to 30/06/2016
PhD theses defended	7
Postdoctoral scientists having spent at least 12 months in the unit	
Number of Research Supervisor Qualifications (HDR) obtained during the period	1

2 • Assessment of the unit

Global assessment of the unit

HERVI has one main objective: to provide new approaches for therapeutic revascularization. Three issues are addressed: (1) the extensive analysis of a thrombus in a stroke model; (2) the study of the participation of endothelial cells in preconditioning; and (3) the potential of cell therapy to improve endovascular revascularization.

With regard to the last evaluation, HERVI research has continued with the original lines of research, valorised by the number and the quality of the scientific production as well as the success in obtaining national and European grants. Thus, HERVI research has remained constant when compared to the results from the previous audit. HERVI has a track record of 231 articles (2011-2016).

In addition, HERVI has developed a strong interaction with local clinicians and regional authorities.

Finally, HERVI is strongly involved in education, has an excellent support from clinicians, as well as of both university and the region.